INTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Intensity Therapeutics Inc (INTS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive momentum, has weak financial performance, and no strong trading signals. While there are some promising developments in its pipeline, the risks outweigh the potential rewards for a beginner investor.
The technical indicators suggest a bearish trend. The MACD is below zero and negatively contracting, the RSI is neutral at 33.52, and the moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 5.639 and resistance at 6.281.
The INVINCIBLE-4 study showed promising results, with 71.4% of early-stage triple-negative breast cancer patients achieving a pathological complete response and a 44% reduction in grade 3 or higher adverse events. The IT-01 study also demonstrated a 75% disease control rate and median overall survival of 11.9 months in heavily pretreated patients. The company has extended its operational runway into Q2 2027 through recent financing.
The company reported a FY GAAP EPS of -$8.56, missing expectations and raising concerns about profitability. The INVINCIBLE-3 study paused new patient enrollments due to funding constraints. Financial performance remains weak, with a net loss of $11.6 million in 2025 and a significant YoY EPS drop of -76.27%.
In Q4 2025, the company reported no revenue growth, a net income loss of -$3,051,000 (down 4.09% YoY), and an EPS of -1.31 (down 76.27% YoY). Gross margin remains at 0%. While the net loss has improved compared to 2024, the financials remain weak overall.
Analysts have a Buy rating on the stock, but recent price target adjustments reflect caution. Freedom Broker upgraded the stock to Buy with a reduced price target of $20, citing valuation and the restart of INVINCIBLE-4 enrollment. Alliance Global adjusted its price target to $30 from $3.50 following a reverse stock split, but the valuation is based on speculative pipeline potential.
